Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  API >  Antineoplastic agents >  Antibiotics anticancer drugs >  Bleomycin hydrochloride

Bleomycin hydrochloride

Basic information Safety Supplier Related

Bleomycin hydrochloride Basic information

Product Name:
Bleomycin hydrochloride
Synonyms:
  • bleomycinchlorhydrate
  • BleomycinA5/Pingyangmycin
  • BleomycinHCl
  • BLEOMYCIN HYDROCHLORIDES
  • BleoMycin A4A5 Hydrochloride
  • BLEOMYCIN HYDROCHLORIDE
  • Bleomycin hydrochloride USP/EP/BP
  • Bleomycin hydrochlorideQ: What is Bleomycin hydrochloride Q: What is the CAS Number of Bleomycin hydrochloride Q: What is the storage condition of Bleomycin hydrochloride
CAS:
67763-87-5
MF:
C50H71N16O21S2R.x(HCl)
MW:
0
Mol File:
Mol File
More
Less

Bleomycin hydrochloride Chemical Properties

storage temp. 
4°C, protect from light
solubility 
DMSO: 125 mg/mL (86.15 mM)
form 
Solid
color 
White to light yellow
More
Less

Bleomycin hydrochloride Usage And Synthesis

Originator

Bleomycin Hydrochloride,Nippon Kayaku, Co.,Japan

Uses

Bleomycin hydrochloride is a DNA synthesis inhibitor. Bleomycin hydrochloride is a DNA damaging agent. Bleomycin hydrochloride is an antitumor antibiotic[1].

Manufacturing Process

To a medium having a composition of 6.4 % of millet jelly, 0.5 % of glucose, 3.5 % of soybean powder, 0.75 % of corn steep liquor, 0.3 % of sodium chloride, 0.1 % of potassium secondary phosphate, 0.05 % of zinc sulfate, 0.01 % of copper sulfate, 0.2 % of sodium nitrate and 0.01 % of Toho No. 1 (trade name for a surface active agent composed of polyoxyethylene manufactured by Toho Chemical Industry Co. Ltd., Japan) was added 3-aminopropyl- dimethylsulfonium bromide hydrobromate in a proportion of 0.4 mg/ml to adjust the pH of the medium to 6.5.
Each 100 ml of the thus treated medium was separately charged into a Sakaguchi flask and was then sterilized. Subsequently, Streptomyces verticillus (ATCC No. 15003) was inoculated in the medium and was cultured at 27°C for 8 days with stirring at 130 r.p.m. Thereafter, the culture liquors (4.5 L) were collected and filtered to obtain 3.0 L of a filtrate (potency 38.8 mg/ml, total potency 416.4 mg). This culture filtrate was passed through and adsorbed on a column packed with 200 ml of Amberlite IRC-50 and was washed with water and was eluted with 0.5 N hydrochloric acid. 1.0 L of the eluate was neutralized, was passed through and adsorbed on a column packed with 100 ml of active carbon, was washed and was then eluted by use of a 1:1 (by volume) mixture of acetone - 0.02 N aqueous hydrochloric acid solution, and fractions active to Mycobacterium 607 were collected and concentrated to dryness. The resulting residue was dissolved in 5 ml of an 80 % aqueous methanol solution and was charged into a column packed with 30 ml of neutral alumina, followed by elution with an 80 % aqueous methanol solution. Subsequently, bleomycin-containing fractions were collected and concentrated to dryness to obtain 195 mg of bleomycin hydrochloride (potency 650.7 mcg/mg, total potency 172 mg). The yield from the culture filtrate was 30.5 %.

Therapeutic Function

Antibiotic

in vivo

Bleomycin hydrochloride ((Bleomycin hydrochloride and Bleomycin sulfate are equivalent)) can be used to create animal models of pulmonary fibrosis. Intratracheal administration of Bleomycin sulfate (3.5-4.0 mg/kg) on day 0 elicits a treatment response, characterized by a decrease in body weight of the subjects on day 4, followed by recovery and continued growth until the end of the experiment. This treatment also significantly increases the levels of hydroxyproline in lung tissue and the mass of the right caudal lobe of the lung. In 8-week-old male BALB/c mice (weighing approximately 20-30 grams), intratracheal instillation of Bleomycin sulfate at a dose of 5.0 mg/kg/day induces pulmonary fibrosis and promotes the expression of α-SMA and type I collagen. Similarly, in 8-week-old male C57BL/6 mice (average weight around 24.5 grams), intratracheal injection of 2.5 mg/kg Bleomycin sulfate effectively induces pulmonary fibrosis. Bleomycin sulfate is rapidly absorbed after administration via intramuscular, subcutaneous, intraperitoneal, or intrapleural routes, reaching peak plasma concentrations within approximately 60 minutes. When given intravenously, less than 1% of the drug binds to plasma proteins, ensuring high bioavailability. The mean plasma clearance rate of Bleomycin sulfate is about 70 mL/min/m2, indicating high plasma elimination and urinary excretion rates[3][4][5][6].

Induction of Pulmonary Fibrosis[7]
Background
Bleomycin sulfate can lead to lung patchy parenchymal inflammation, epithelial cell injury with reactive hyperplasia, epithelial-mesenchymal transition, activation and differentiation of fibroblasts to myofibroblasts, and basement membrane and alveolar epithelium injures. The experimental use of Bleomycin sulfate is to induce pulmonary fibrosis animal models.
Specific Modeling Methods
Mice: C57BL/6 ? 12-week-old
Administration: 3-5 mg/kg ? intratracheal administration ? sprays on day one
Note
The mice were housed in separate stainless-steel cages (six mice per cage) in a temperature-controlled environment (20-24°C) on 12 h light-dark cycles with unrestricted access to food and water.
Modeling Indicators
Body quality changes: The appetite activity is reduced, with the fur less shiny, the spirits being lethargic, and the bodyweight decreasing. Showed shortness of breath, coughing, and noisy.
Lung changes: Increased fibrotic consolidations, non-aerated lung area, and high-density lung area. Pulmonary function decreased.
Molecular changes: Increased indicators: TGF-β1, TNF-α, IL-6, and GM-CSF in bronchoalveolar lavage fluid.
Correlated Product(s): Bleomycin hydrochloride (HY-17565A)
Opposite Product(s): Neotuberostemonine (HY-N3196)

Animal Model:Male Fischer 344 rats, 8-10 week old, weighing 150-250?g[3]
Dosage:3.5-4 mg/kg
Administration:Intra-tracheal
Result:Body weights decreased by day 4 then increased by Day 7 through the end of the study.

References

[1] Hovhannisyan G, et al. Comparative analysis of individual chromosome involvement in micronuclei induced by bleomycin in human leukocytes. Mol Cytogenet. 2016 Jun 21;9:49. DOI:10.1186/s13039-016-0258-4
[2] Jaaskela-Saari HA, et al. Squamous cell cancer cell lines: sensitivity to bleomycin and suitability for animal xenograft studies. Acta Otolaryngol Suppl. 1997;529:241-4. DOI:10.3109/00016489709124133
[3] Corboz MR, et al. Therapeutic administration of inhaled INS1009, a LRX-15 prodrug formulation, inhibits bleomycin-induced pulmonary fibrosis in rats. Pulm Pharmacol Ther. 2018 Apr;49:95-103. DOI:10.1016/j.pupt.2018.01.012
[4] Kang Miao, et al. Scutellarein inhibits BLM-mediated pulmonary fibrosis by affecting fibroblast differentiation, proliferation, and apoptosis. Ther Adv Chronic Dis. 2020 Jul 30;11:2040622320940185. DOI:10.1177/2040622320940185
[5] Ling Peng, et al. Scutellarin ameliorates pulmonary fibrosis through inhibiting NF-κB/NLRP3-mediated epithelial-mesenchymal transition and inflammation. Cell Death Dis. 2020 Nov 13;11(11):978. DOI:10.1038/s41419-020-03178-2

Bleomycin hydrochlorideSupplier

Zhejiang Hisun Pharmaceutical Co., Ltd. Gold
Tel
0576-88827984
Email
sale@hisunpharm.com
Shanghai Rechem science Co., Ltd. Gold
Tel
021-31433387 15618786686
Email
sales@rechemscience.com
Shanghai Witofly Chemical Co.,Ltd
Tel
Email
sales@witofly.com
AdooQ BioScience, LLC
Tel
+1 (866) 930-6790
Email
info@adooq.com
ShangHai Caerulum Pharma Discovery Co., Ltd.
Tel
18149758185
Email
sales-cpd@caerulumpharma.com